Usefulness of screening for Candida auris colonisation in international patients admitted to a large university hospital.
C. auris
Germany
colonisation
foreign patients
screening
university hospital
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
06
09
2022
received:
15
06
2022
accepted:
14
09
2022
pubmed:
23
9
2022
medline:
12
1
2023
entrez:
22
9
2022
Statut:
ppublish
Résumé
Candida auris is an emerging pathogen in health care-associated infections. In contrast to many other countries with rising numbers of C. auris, only seven cases have been reported in Germany from 2015 to 2017, mostly from patients who received prior medical treatment abroad. We therefore established a mandatory screening for C. auris colonisation at our tertiary care centre for all patients who were admitted as international patients or previously hospitalised in a foreign country within the past 6 months. Colonisation of patients was assessed using a previously established screening protocol for multidrug resistant bacteria. Since 2017, all screening samples were additionally analysed for C. auris using CHROMagar Candida (CHROMagar, Paris, France). Yeast isolates were identified using matrix-assisted laser ionisation time-of-flight (MALDI TOF), except for C. albicans (identified by the typical green colour on chromogenic agar). Data were analysed retrospectively. Our study cohort included 655 patients and an overall number of 1399 samples. Fifty-three patients were colonised with Candida species (C. albicans, n = 37; C. glabrata, n = 14; others n = 9). No case of C. auris was detected. Candida spp. were mainly detected from respiratory samples (5.4% positive) and gastrointestinal specimen (5.2%). Laboratory costs were 14,689 € and analyses resulted in 98.7 h of additional technician's work. No colonisation with C. auris was detected among patients with previous hospitalisation abroad. Universal C. auris screening of patients with any contact to foreign health care does not seem to be cost-effective in our setting and more targeted screening strategies have to be developed.
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-143Informations de copyright
© 2022 The Authors. Mycoses published by Wiley-VCH GmbH.
Références
Schelenz S, Hagen F, Rhodes JL, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35. doi:10.1186/s13756-016-0132-5
Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134-140. doi:10.1093/cid/ciw691
Kathuria S, Singh PK, Sharma C, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015;53(6):1823-1830. doi:10.1128/JCM.00367-15
Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41-44. doi:10.1111/j.1348-0421.2008.00083.x
European Centre for Disease Prevention and Control. Rapid Risk Assessment: Candida Auris Outbreak in Healthcare Facilities in Northern Italy, 2019-2021; 2022. Accessed June 7, 2022. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-candida-auris-outbreak-healthcare-facilities-northern-italy
Osei SJ. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiology. 2018;7(4):e00578. doi:10.1002/mbo3.578
Kohlenberg A, Struelens MJ, Monnet DL, Plachouras D. Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European economic area countries, 2013 to 2017. Euro Surveill. 2018;23(13). doi:10.2807/1560-7917.ES.2018.23.13.18-00136
Plachouras D, Lötsch F, Kohlenberg A, Monnet DL. Candida auris: epidemiological situation, laboratory capacity and preparedness in the European Union and European economic area*, January 2018 to may 2019. Euro Surveill. 2020;25(12). doi:10.2807/1560-7917.ES.2020.25.12.2000240
Hamprecht A, Barber AE, Mellinghoff SC, et al. Candida auris in Germany and previous exposure to foreign healthcare. Emerg Infect Dis. 2019;25(9):1763-1765. doi:10.3201/eid2509.190262
Steinmann J, Schrauzer T, Kirchhoff L, Meis JF, Rath P-M. Two Candida auris cases in Germany with no recent contact to foreign healthcare-epidemiological and microbiological investigations. J Fungi (Basel). 2021;7(5):380. doi:10.3390/jof7050380
European Centre for Disease Prevention and Control. Rapid Risk Assessment: Candida Auris in Healthcare Settings - Europe. 2018. Accessed May 23, 2022. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-candida-auris-healthcare-settings-europe
Sharp A, Muller-Pebody B, Charlett A, et al. Screening for Candida auris in patients admitted to eight intensive care units in England, 2017 to 2018. Euro Surveill. 2021;26(8):1900730. doi:10.2807/1560-7917.ES.2021.26.8.1900730
Public Health England. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR): Report 2018-2019. 2019. Accessed May 23, 2022. https://webarchive.nationalarchives.gov.uk/ukgwa/20200806045257/https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report
Hygienemaßnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen Stäbchen. Empfehlung der Kommission für Kranken-haushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (RKI). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012;55(10):1311-1354. doi:10.1007/s00103-012-1549-5
Brooks RB, Walters M, Forsberg K, Vaeth E, Woodworth K, Vallabhaneni S. Candida auris in a U.S. patient with Carbapenemase-producing organisms and recent hospitalization in Kenya. MMWR Morb Mortal Wkly Rep. 2019;68(30):664-666. doi:10.15585/mmwr.mm6830a3
Vogelzang EH, Weersink AJL, van Mansfeld R, Chow NA, Meis JF, van Dijk K. The first two cases of Candida auris in The Netherlands. J Fungi (Basel). 2019;5(4):91. doi:10.3390/jof5040091
Ruiz-Azcona L, Santibañez M, Roig FJ, et al. Isolation of Candida auris in large hospitals in the autonomous Community of Valencia; population-based study (2013-2017). Rev Iberoam Micol. 2021;38(3):141-144. doi:10.1016/j.riam.2021.01.005
García CS, Palop NT, Bayona JVM, et al. Candida auris: descripción de un brote. Enferm Infecc Microbiol Clin (Engl ed). 2020;38(Suppl 1):39-44. doi:10.1016/j.eimc.2020.02.007
Eyre DW, Sheppard AE, Madder H, et al. A Candida auris outbreak and its control in an intensive care setting. N Engl J Med. 2018;379(14):1322-1331. doi:10.1056/NEJMoa1714373
Hinrichs C, Wiese-Posselt M, Graf B, et al. Successful control of Candida auristransmission in a German COVID-19 intensive care unit. Mycoses. 2022;65:643-649. doi:10.1111/myc.13443
Al-Rashdi A, Al-Maani A, Al-Wahaibi A, Alqayoudhi A, Al-Jardani A, Al-Abri S. Characteristics, risk factors, and survival analysis of Candida auris cases: results of one-year National Surveillance Data from Oman. J Fungi (Basel). 2021;7(1):31. doi:10.3390/jof7010031
Leach L, Russell A, Zhu Y, Chaturvedi S, Chaturvedi V. A rapid and automated sample-to-result Candida auris real-time PCR assay for high-throughput testing of surveillance samples with the BD max open system. J Clin Microbiol. 2019;57(10):e00630-19. doi:10.1128/JCM.00630-19
Aldejohann AM, Wiese-Posselt M, Gastmeier P, Kurzai O. Expert recommendations for prevention and management of Candida auris transmission. Mycoses. 2022;65(6):590-598. doi:10.1111/myc.13445
Screening for Candida auris Colonization|Candida auris|Fungal Diseases|CDC. Published June 14, 2019. Accessed May 23, 2022. https://www.cdc.gov/fungal/candida-auris/c-auris-screening.html
European Centre for Disease Prevention and Control. Rapid Risk Assessment: Candida Auris in Healthcare Settings - Europe. 2016. Accessed May 23, 2022. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Candida-in-healthcare-settings_19-Dec-2016.pdf.
Borman AM, Fraser M, Johnson EM. CHROMagarTM Candida plus: a novel chromogenic agar that permits the rapid identification of Candida auris. Med Mycol. 2021;59(3):253-258. doi:10.1093/mmy/myaa049
Sattler J, Noster J, Brunke A, et al. Comparison of two commercially available qPCR kits for the detection of Candida auris. J Fungi (Basel). 2021;7(2):154. doi:10.3390/jof7020154